Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03994601	TitleAn Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers	Phase Phase 1	Date Added 2019-06-21	Location California, United States Colorado, United States Maryland, United States Missouri, United States New Jersey, United States Argentina Canada Chile France Italy Spain	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs BMS-986288, Nivolumab, Opdivo	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03970382	TitleA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors	Phase Phase 1	Date Added 2019-05-31	Location California, United States Illinois, United States New York, United States Tennessee, United States Washington, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Suspended	Drugs IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab	Tags MSS/ MMRp
NCT ID NCT03983993	TitleNiraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2019-06-12	Location Georgia, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Niraparib, panitumumab, Vectibix, Zejula	Tags MSS/ MMRp
NCT ID NCT03745326	TitleAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients	Phase Phase 1, Phase 2	Date Added 2018-11-19	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03280511	TitleAdjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients	Phase Phase 2	Date Added 2017-09-12	Location Denmark	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs PIPAC	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05141474	TitleAssessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors	Phase Early Phase 1	Date Added 2021-12-02	Location Spain	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05215574	TitleStudy of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2022-01-31	Location Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs NGM831, NGM831 plus pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04332653	TitleNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors	Phase Phase 1	Date Added 2020-04-03	Location Florida, United States Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs NT-I7, Pembrolizumab	Tags MSS/ MMRp
NCT ID NCT03851614	TitleBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors	Phase Phase 2	Date Added 2019-02-22	Location Canada	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Cediranib, durvalumab, Olaparib	Tags MSS/ MMRp
NCT ID NCT03832855	TitleAssessing the Immunogenicity of pING-hHER3FL	Phase Phase 1	Date Added 2019-02-06	Location North Carolina, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs pING-hHER3FL	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 111 to 120 of 299 entries